

---

**INFORMATION ONLY****Compatibility Testing Interference Risk in Patients Being Treated with Sarclisa™ (Isatuximab)**  
**Customer Letter # 2020-42**

---

2020-09-24

Dear Colleagues:

Please see the attached important letter from Sanofi Genzyme regarding risk of interference with blood compatibility testing in patients being treated with Sarclisa™ (Isatuximab).

Please share a copy of this customer letter with healthcare professionals at your hospital who might be interested in this information.

This customer letter can also be viewed at [www.blood.ca](http://www.blood.ca) in the “Hospitals Services” section. If you have questions about this letter, or if you require it in an accessible format, please contact your local hospital liaison specialist.

Sincerely,



Dr. Gwen Clarke  
Associate Medical Director  
Donor & Clinical Services